Recent News for ZLAB - Zai Lab Limited

Date Title
Jan 17 The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
Jan 15 Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
Jan 9 Zia Lab completes enrollment in China-based study of niraparib in ovarian cancer
Jan 9 Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China
Dec 28 Zai Lab launches Optune in Hong Kong for patients with GBM
Dec 28 Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme
Dec 19 Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 16 Zai Lab Limited (ZLAB): Are Hedge Funds Right About This Stock?
Dec 12 Zai Lab's NDA for ZEJULA accepted in China
Dec 12 Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA
Dec 3 George Soros Bought These 2 Healthcare Stocks in the Third Quarter
Nov 29 MacroGenics teams up with Zai Lab in three cancer programs in Greater China
Nov 29 MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
Nov 14 Zai Lab and Novocure Awarded Deal of the Year
Nov 9 Key events next week - healthcare
Nov 7 Zai Lab Limited Announces Presentations at November Conferences
Oct 22 Zai Lab' ZEJULA for patients with relapsed ovarian cancer approved in Hong Kong
Oct 22 Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
Oct 12 The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Oct 10 Cancer Research Highlight: Five Prime Moves To Prime Time With A New Phase 3 Trial Off The Ground
Oct 1 Dosing underway in late-stage study of Five Prime's bemarituzumab in gastric cancer
Oct 1 Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Sep 27 Zai Lab appoints Tao Fu as President & Chief Operating Officer
Sep 27 Chinese Market Opportunity Could Drive Zai Lab’s Revenue Growth
Sep 27 Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence

Back to the Main ZLAB Page...